Phenytoin Sodium - Revision history

Helen: /* Dosage */

2020-10-12T07:53:08Z

Dosage

← Older revision		Revision as of 03:53, 12 October 2020
Line 34:		Line 34:
	==Dosage==		==Dosage==
	Doses may be expressed in terms of phenytoin or phenytoin sodium; phenytoin 92 mg is equivalent to about 100 mg phenytoin sodium.		Doses may be expressed in terms of phenytoin or phenytoin sodium; phenytoin 92 mg is equivalent to about 100 mg phenytoin sodium.

			As phenytoin has a narrow therapeutic index, need to monitor plasma-phenytoin concentration.

	{\| class="wikitable"		{\| class="wikitable"
	~~!style="text-align: left"\| As phenytoin has a narrow therapeutic index, need to monitor plasma-phenytoin concentration.~~
	\|
	\|-
	!style="text-align: left"\| Anticonvulsant effect		!style="text-align: left"\| Anticonvulsant effect
	\|10-20 micrograms/mL (40 to 80 micromoles/litre)		\|10-20 micrograms/mL (40 to 80 micromoles/litre)

Helen: /* Dosage */

2020-10-12T07:48:57Z

Dosage

← Older revision		Revision as of 03:48, 12 October 2020
Line 49:		Line 49:
	!style="text-align: left"\| By mouth		!style="text-align: left"\| By mouth
	\|initially 3-4 mg/kg daily or 150 – 300 mg daily (as a single dose or in 2 divided doses) increased gradually as necessary to 600 mg daily. The suggested minimum interval between increments has ranged from about 7 to 10 days. A usual maintenance dose is 200 – 500 mg daily.		\|initially 3-4 mg/kg daily or 150 – 300 mg daily (as a single dose or in 2 divided doses) increased gradually as necessary to 600 mg daily. The suggested minimum interval between increments has ranged from about 7 to 10 days. A usual maintenance dose is 200 – 500 mg daily.
	\|-		\|}

	For doses in children.		For doses in children.
			{\| class="wikitable"
	!style="text-align: left"\| By mouth		!style="text-align: left"\| By mouth
	\|initially 5 mg/kg daily in 2 divided doses, usual dose range 4-8 mg/kg daily (max. 300 mg daily)		\|initially 5 mg/kg daily in 2 divided doses, usual dose range 4-8 mg/kg daily (max. 300 mg daily)

Helen: /* Dosage */

2020-10-12T07:47:33Z

Dosage

← Older revision		Revision as of 03:47, 12 October 2020
Line 46:		Line 46:
	\|}		\|}

	''By mouth~~'',~~ initially 3-4 mg/kg daily or 150 – 300 mg daily (as a single dose or in 2 divided doses) increased gradually as necessary to 600 mg daily. The suggested minimum interval between increments has ranged from about 7 to 10 days. A usual maintenance dose is 200 – 500 mg daily.		{\| class="wikitable"
			!style="text-align: left"\| By mouth
			\|initially 3-4 mg/kg daily or 150 – 300 mg daily (as a single dose or in 2 divided doses) increased gradually as necessary to 600 mg daily. The suggested minimum interval between increments has ranged from about 7 to 10 days. A usual maintenance dose is 200 – 500 mg daily.
			\|-
	For doses in children.		For doses in children.
			!style="text-align: left"\| By mouth
			\|initially 5 mg/kg daily in 2 divided doses, usual dose range 4-8 mg/kg daily (max. 300 mg daily)
			\|}

	To lessen gastric irritation, phenytoin should be taken with or after food.		To lessen gastric irritation, phenytoin should be taken with or after food.

Helen: /* Dosage */

2020-10-12T07:45:43Z

Dosage

← Older revision		Revision as of 03:45, 12 October 2020
Line 36:		Line 36:

	{\| class="wikitable"		{\| class="wikitable"
	!As phenytoin has a narrow therapeutic index, need to monitor plasma-phenytoin concentration.		!style="text-align: left"\| As phenytoin has a narrow therapeutic index, need to monitor plasma-phenytoin concentration.
	\|		\|
	\|-		\|-

Helen: /* Dosage */

2020-10-12T07:45:16Z

Dosage

← Older revision		Revision as of 03:45, 12 October 2020
Line 41:		Line 41:
	!style="text-align: left"\| Anticonvulsant effect		!style="text-align: left"\| Anticonvulsant effect
	\|10-20 micrograms/mL (40 to 80 micromoles/litre)		\|10-20 micrograms/mL (40 to 80 micromoles/litre)
			\|-
	!style="text-align: left"\| Antiarrhythmic effect		!style="text-align: left"\| Antiarrhythmic effect
	\|10-20 micrograms/mL (40 to 80 micromoles/litre)		\|10-20 micrograms/mL (40 to 80 micromoles/litre)

Helen: /* Dosage */

2020-10-12T07:45:04Z

Dosage

← Older revision		Revision as of 03:45, 12 October 2020
Line 38:		Line 38:
	!As phenytoin has a narrow therapeutic index, need to monitor plasma-phenytoin concentration.		!As phenytoin has a narrow therapeutic index, need to monitor plasma-phenytoin concentration.
	\|		\|
			\|-
	!style="text-align: left"\| Anticonvulsant effect		!style="text-align: left"\| Anticonvulsant effect
	\|10-20 micrograms/mL (40 to 80 micromoles/litre)		\|10-20 micrograms/mL (40 to 80 micromoles/litre)

Helen: /* Dosage */

2020-10-12T07:44:55Z

Dosage

← Older revision		Revision as of 03:44, 12 October 2020
Line 37:		Line 37:
	{\| class="wikitable"		{\| class="wikitable"
	!As phenytoin has a narrow therapeutic index, need to monitor plasma-phenytoin concentration.		!As phenytoin has a narrow therapeutic index, need to monitor plasma-phenytoin concentration.
	\|-		\|
	!style="text-align: left"\| Anticonvulsant effect		!style="text-align: left"\| Anticonvulsant effect
	\|10-20 micrograms/mL (40 to 80 micromoles/litre)		\|10-20 micrograms/mL (40 to 80 micromoles/litre)

Helen: /* Dosage */

2020-10-12T07:44:42Z

Dosage

← Older revision		Revision as of 03:44, 12 October 2020
Line 36:		Line 36:

	{\| class="wikitable"		{\| class="wikitable"
	!As phenytoin has a narrow therapeutic index, need to monitor plasma-phenytoin concentration.		!As phenytoin has a narrow therapeutic index, need to monitor plasma-phenytoin concentration.
			\|-
	!style="text-align: left"\| Anticonvulsant effect		!style="text-align: left"\| Anticonvulsant effect
	\|10-20 micrograms/mL (40 to 80 micromoles/litre)		\|10-20 micrograms/mL (40 to 80 micromoles/litre)

Helen: /* Dosage */

2020-10-12T07:44:29Z

Dosage

← Older revision		Revision as of 03:44, 12 October 2020
Line 33:		Line 33:

	==Dosage==		==Dosage==

	Doses may be expressed in terms of phenytoin or phenytoin sodium; phenytoin 92 mg is equivalent to about 100 mg phenytoin sodium.		Doses may be expressed in terms of phenytoin or phenytoin sodium; phenytoin 92 mg is equivalent to about 100 mg phenytoin sodium.

	As phenytoin has a narrow therapeutic index, need to monitor plasma-phenytoin concentration.		{\| class="wikitable"
			!As phenytoin has a narrow therapeutic index, need to monitor plasma-phenytoin concentration.
	Anticonvulsant effect: 10-20 micrograms/mL (40 to 80 micromoles/litre)		!style="text-align: left"\| Anticonvulsant effect
			\|10-20 micrograms/mL (40 to 80 micromoles/litre)
	Antiarrhythmic effect: 10-20 micrograms/mL (40 to 80 micromoles/litre)		!style="text-align: left"\| Antiarrhythmic effect
			\|10-20 micrograms/mL (40 to 80 micromoles/litre)
			\|}

	''By mouth'', initially 3-4 mg/kg daily or 150 – 300 mg daily (as a single dose or in 2 divided doses) increased gradually as necessary to 600 mg daily. The suggested minimum interval between increments has ranged from about 7 to 10 days. A usual maintenance dose is 200 – 500 mg daily.		''By mouth'', initially 3-4 mg/kg daily or 150 – 300 mg daily (as a single dose or in 2 divided doses) increased gradually as necessary to 600 mg daily. The suggested minimum interval between increments has ranged from about 7 to 10 days. A usual maintenance dose is 200 – 500 mg daily.

Helen: /* Drug Management */

2020-10-12T07:42:41Z

Drug Management

← Older revision		Revision as of 03:42, 12 October 2020
Line 237:		Line 237:
	\|}		\|}

	~~'''~~Caution:		===Caution===
	*Avoid abrupt withdrawal		*Avoid abrupt withdrawal
	*Caution in diabetic patients because of the potential effects phenytoin on blood sugar		*Caution in diabetic patients because of the potential effects phenytoin on blood sugar
Line 245:		Line 245:
	*enteral feeding (interrupt feeding for 2 hours before and after dose)		*enteral feeding (interrupt feeding for 2 hours before and after dose)

	~~'''~~Contraindications		===Contraindications===
	*AV conduction abnormalities		*AV conduction abnormalities
	*History of bone-marrow depression		*History of bone-marrow depression
	*Acute porphyria		*Acute porphyria

	~~'''~~Hepatic impairment		===Hepatic impairment===
	Phenytoin is metabolized in the liver and should be given with care to patients with impaired liver function. Reduce dose to avoid toxicity.		Phenytoin is metabolized in the liver and should be given with care to patients with impaired liver function. Reduce dose to avoid toxicity.

	~~'''~~Renal impairment		===Renal impairment===
	Can begin with standard dose and adjust as needed		Can begin with standard dose and adjust as needed

	~~'''~~Pregnancy		===Pregnancy===
	Women of child-bearing potential should discuss with a specialist the impact of both epilepsy, and its treatment, on the outcome of pregnancy. There is an increased risk of teratogenicity associated with the use of antiepileptic drug (especially if used during the first trimester)		Women of child-bearing potential should discuss with a specialist the impact of both epilepsy, and its treatment, on the outcome of pregnancy. There is an increased risk of teratogenicity associated with the use of antiepileptic drug (especially if used during the first trimester)

	~~'''~~Breast-feeding		===Breast-feeding===
	Use during breast feeding is not recommended.		Use during breast feeding is not recommended.

	Epilepsy and driving		===Epilepsy and driving===
	Driving by patients with epilepsy is generally regulated. Also, antiepileptic drugs may produce CNS-related adverse effects, including dizziness and drowsiness, that could impair a patient’s ability to drive a vehicle or operate machinery, particularly during the initial stages of therapy.		Driving by patients with epilepsy is generally regulated. Also, antiepileptic drugs may produce CNS-related adverse effects, including dizziness and drowsiness, that could impair a patient’s ability to drive a vehicle or operate machinery, particularly during the initial stages of therapy.